Arcellx, Inc. - Common Stock (ACLX)

A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025.

As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is currently witnessing an unprecedented resurgence in Mergers and Acquisitions (M&A). This revival is being fueled by a

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.